Recruiting

Deep Brain Stimulation

Sponsor:

Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)

Code:

NCT04354077

Conditions

Opioid-use Disorder

Eligibility Criteria

Sex: All

Age: 22 - 65

Healthy Volunteers: Not accepted

Interventions

DBS of the NAc

Study Details

Brief summary:

This is a pilot study to evaluate the safety and efficacy of deep brain stimulation (DBS) of the nucleus accumbens (NAc) as adjunctive treatment for treatment-refractory opioid use disorder. This study will include 3 individuals with opioid use disorder and relapsing opioid use despite active participation in a drug addiction treatment program.

Conditions

Opioid-use Disorder

Study ID

NCT04354077

Start date

Feb 7, 2022

Status verified date

Aug, 2026

Completion date

Jan, 2030

Anticipated

Primary completion date

Jan, 2029

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 22 - 65

Healthy Volunteers: Not accepted

Inclusion criteria

1. Male and females age ≥ 22 years with diagnosis of opioid use disorder (OUD) based on Diagnostic and Statistical Manual of Mental Disorders, fifth edition (DSM-5) with at least a 5-year history
2. OUD must be the primary disorder
3. History of ongoing or previous opioid use, relapse, and/or cravings, despite attempts at, or attendance in, at least two different treatment modalities. These modalities may include: Comprehensive Opioid Addiction Treatment (COAT), intensive outpatient COAT, residential treatment, inpatient treatment, alternative to intensive outpatient programs, Drug Dependence Unit programs, medication-assisted treatment (MAT), medication assisted recovery (MAR), inpatient or outpatient rehabilitation, detox programs, Narcotics Anonymous, individual or group therapy, Partial Hospitalization Programs (PHP), Sober living homes, or similar interventions.
4. Self-reports ongoing opioid cravings.
5. Has completed a neuro-psychological evaluation to the satisfaction of a neuropsychologist
6. Has completed a psychiatric evaluation to the satisfaction of a psychiatrist
7. Has had a brain MRI performed and reviewed by neurosurgeon with no contraindication for DBS procedure identified
8. Platelet count > 125,000 per cubic mm and prothrombin time (PT) and partial thromboplastin time (PTT) within normal limits
9. Negative blood cultures to rule out bacteremia

Exclusion criteria

1. Prior brain surgery contraindicating Deep Brain Stimulation (DBS) surgery, including procedures that required a craniotomy (e.g., brain tumor removal, trauma or pressure relief, hemorrhage, or clot evacuation). Patients with other brain surgery history will be considered and approved at the discretion of the Principal Investigator (PI).
2. Baseline assessment on the Hamilton Depression Rating Scale (HAMD) of greater than 17 or moderate risk of suicide based upon a score of 3 or greater on the Columbia Suicide Severity Scale, unless clinical judgment indicates that the individual is appropriate for inclusion despite these scores.
3. History of uncontrolled or persistent seizures
4. Suspected dementia based on neuropsychological screening or Mini Mental State Exam (MMSE) Score < 25
5. Contraindications for MRI:

1. Presence of implanted electrical stimulation device or other implanted metal devices (excluding dental braces).
2. Claustrophobia
3. Body weight exceeding limit of the machine (180 kg/400 lb)
6. Females who are pregnant or nursing. Female subjects of child-bearing potential must have a negative pregnancy test during the pre-op phase and must agree to utilize adequate birth control throughout the trial and for at least 30 days following trial completion.
7. Coagulopathy secondary to chronic need for anticoagulation medicine (e.g. warfarin) or anti-platelet medication (e.g. aspirin or clopidogrel)
8. Diagnosis of neurological disorders (e.g. multiple sclerosis, Parkinson's disease, and stroke)
9. Severe brain atrophy or presence of subdural hygromas or subdural hematomas on brain MRI
10. Any evidence of underlying endocarditis.
11. Primary language other than English
12. Have any other medical condition that, in the opinion of the Investigator, makes the subject unsuitable for enrollment.

Study Design

Enrollment

3 participants

Anticipated

Intervention Model

Single group

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: NAc DBS

Subjects will receive bilateral DBS of the NAc

Interventions

DBS of the NAc

Deep Brain Stimulation of the Nucleus Accumbens

Primary outcome measure

  • Opioid use/abstinence [ Time Frame: 6 months ]
  • Opioid use/abstinence [ Time Frame: 1 year post-surgery ]

Central Contacts and Locations

Central contacts

Locations

AHN Allegheny General Hospital

Recruiting

Pittsburgh, Pennsylvania, United States, 15212

Contacts

Clinical Trials Contact

clinicaltrials@ahn.org

Principal Investigator:

Nestor Tomycz, MD

More Information

Sponsor

Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)

Last update posted

Aug 31, 2026

Last verified

Aug, 2026

Keywords

  • Deep Brain Stimulation
  • Addiction
  • Nucleus Accumbens

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute) on 2026-08-31.